All entries on CureVac N.V across all areas, newest first. tag:eurotrack.ai,2026:en:en/companies/curevac 2025-11-25T06:00:00Z Eurotrack tag:eurotrack.ai,2026:27b16f63:en 2025-11-25T06:00:00Z

CureVac shareholders voted with over 99% in favour of the takeover by BioNTech. The exchange offer runs until 3 December 2025, with CureVac shares being exchanged for BioNTech ADS. Antitrust approval is in place. CureVac will be delisted and integrated into BioNTech. The open legal dispute with Pfizer/BioNTech was suspended. Update (18.12.2025): BioNTech closed its acquisition of CureVac on 18.12.2025; the compulsory acquisition of the remaining shares and the end of trading in CureVac shares were scheduled for January 2026 as part of the post-offer reorganisation (BioNTech press release via BioSpace, 18.12.2025). — Source: https://www.msn.com/de-de/finanzen/top-stories/fusion-mit-biontech-curevac-aktion%C3%A4re-haben-entschieden-so-reagieren-die-aktien/ar-AA1RaVjE

tag:eurotrack.ai,2026:59349f3f:en 2025-10-22T06:00:00Z

BioNTech is launching a public exchange offer for the full takeover of CureVac; the all-stock deal values CureVac at around $1.25 billion. Update (6 January 2026): The takeover is complete — after the exchange offer, BioNTech took over all remaining CureVac shares through a post-offer reorganisation and is now the sole owner; Nasdaq trading was suspended on 6 January 2026 and the delisting took effect on 16 January 2026 (Panabee, 6 January 2026). — Source: https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2025/10/biontech-commences-public-exchange-offer-all-outstanding-shares.html